Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Insmed Incorporated (INSM)

25.37   0.12 (0.48%) 10-02 16:00
Open: 25.25 Pre. Close: 25.25
High: 25.52 Low: 24.99
Volume: 1,082,854 Market Cap: 3,648(M)

Technical analysis

as of: 2023-10-02 4:51:01 PM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 32.22     One year: 37.63
Support: Support1: 23.64    Support2: 21.2
Resistance: Resistance1: 27.59    Resistance2: 32.22
Pivot: 26.08
Moving Average: MA(5): 25.61     MA(20): 26.16
MA(100): 21.69     MA(250): 20.17
MACD: MACD(12,26): 0.5     Signal(9): 0.8
Stochastic oscillator: %K(14,3): 15.4     %D(3): 18.5
RSI: RSI(14): 53.4
52-week: High: 27.59  Low: 16.04
Average Vol(K): 3-Month: 1,350 (K)  10-Days: 1,059 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ INSM ] has closed above bottom band by 13.5%. Bollinger Bands are 24% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 25.56 - 25.7 25.7 - 25.83
Low: 24.61 - 24.8 24.8 - 24.97
Close: 25.1 - 25.37 25.37 - 25.62

Company Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Headline News

Wed, 27 Sep 2023
Can Insmed Incorporated (INSM) Stock Rise to the Top of Healthcare Sector Wednesday? - InvestorsObserver

Tue, 26 Sep 2023
Insmed To Present at Chardan's 7th Annual Genetic Medicines ... - PR Newswire

Wed, 20 Sep 2023
Insmed Incorporated (NASDAQ:INSM) Given Consensus ... - MarketBeat

Mon, 11 Sep 2023
Suvretta Capital Management LLC Grows Stock Holdings in Insmed ... - MarketBeat

Fri, 08 Sep 2023
Insmed Reports Inducement Grants Under NASDAQ Listing Rule ... - PR Newswire

Wed, 06 Sep 2023
Insmed To Present at the Morgan Stanley 21st Annual Global ... - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 144 (M)
Shares Float 142 (M)
% Held by Insiders 1.2 (%)
% Held by Institutions 109.4 (%)
Shares Short 12,440 (K)
Shares Short P.Month 10,190 (K)

Stock Financials

EPS -5.43
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.1
Profit Margin (%) -258.3
Operating Margin (%) -243.3
Return on Assets (ttm) -32.9
Return on Equity (ttm) 0
Qtrly Rev. Growth 18.3
Gross Profit (p.s.) 1.32
Sales Per Share 1.87
EBITDA (p.s.) -4.51
Qtrly Earnings Growth 0
Operating Cash Flow -462 (M)
Levered Free Cash Flow -301 (M)

Stock Valuations

PE Ratio -4.68
PEG Ratio 0
Price to Book value -23.28
Price to Sales 13.53
Price to Cash Flow -7.9

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.